Trial Profile
To Assess Benefit risk and medical cost of direct oral anticoagulants versus low ‐ molecular ‐ weight heparins for venous thromboembolism prevention following total knee replacement. A French nationwide cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Low molecular weight heparins (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 24 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management